Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.41 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 2/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.41 |
| ▸ | SI | P14410 | 2/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820216 | 0.98 | ALDH1A1 (0.46) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL2954276 | 0.97 | ALDH1A1 (0.48) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6535470 | 0.85 | PTPN1 (0.43) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3846709 | 0.84 | RAB9A (0.43) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL5004650 | 0.84 | PTPN1 (0.42) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL3845607 | 0.84 | PTPN1 (0.42) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6938200 | 0.84 | ALDH1A1 (0.49) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6535050 | 0.83 | ALDH1A1 (0.40) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL3849504 | 0.82 | PTPN1 (0.44) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6535191 | 0.82 | ALDH1A1 (0.43) | RAB9AKDM4EMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122328-A1 | COMPOSITIONS AND METHODS FOR VASCULAR STABILIZATION | BARD PERIPHERAL VASCULAR, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| CN-119349535-A | Carbon-coated lithium iron manganese phosphate, preparation method thereof, positive plate and lithium ion battery | 合肥国轩高科动力能源有限公司 | 2025-01-24 | — | — | CN | claimed |
| US-20250025048-A1 | Liver Viscoelastic Changes and Biomarkers for Cancer Invasion | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-01-23 | — | — | US | claimed |
| CN-116789577-A | Preparation method of mesotrione compounds | 北京颖泰嘉和生物科技股份有限公司 | 2023-09-22 | — | — | CN | claimed |
| WO-2023102546-A1 | LIVER VISCOELASTIC CHANGES AND BIOMARKERS FOR CANCER INVASION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-06-08 | — | — | WO | claimed |
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | claimed |
| US-20100152125-A1 | Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases | BRANDEIS UNIVERSITY (US) | 2010-06-17 | — | — | US | claimed |
| EP-2139460-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES | Brandeis University (US) | 2010-01-06 | — | — | EP | claimed |
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | claimed |
| EP-1865955-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | Merck & Co., Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1353669-B1 | METHOD FOR TREATING GLAUCOMA | ALTEON INC (US) | 2007-08-15 | — | — | EP | claimed |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2007-02-01 | — | — | US | claimed |
| WO-2006104762-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | claimed |
| US-7022719-B2 | Preventing and reversing the formation of advance glycosylation endproducts | ALTEON, INC. (US) | 2006-04-04 | — | — | US | claimed |
| EP-1592435-A1 | OPHTHALMIC FORMULATION FOR THE PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Chakshu Research, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | claimed |
| US-20040137068-A1 | Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye | LIVIONEX INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004058289-A1 | OPHTHALMIC FORMULATION FOR THE PREVENTION AND TREATMENT OF OCULAR CONDITIONS | CHAKSHU RESEARCH, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040034074-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2004-02-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | GAA 293/4885GRIN2B 3921/4885RAB9A 2851/4885 |
| US-20100152125-A1 | Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases | SOD1, SOD3, AGER | GAA 17/4885GRIN2B 1438/4885RAB9A 3769/4885 |
| US-20040034074-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | GAA 41/4885GRIN2B 4765/4885RAB9A 3838/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | GAA 181/4885GRIN2B 2954/4885RAB9A 3397/4885 |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | GAA 41/4885GRIN2B 4765/4885RAB9A 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.